Deepak Dsouza, MBBS, MD

Professor of Psychiatry; Director Schizophrenia Neuropharmacology Research Group at Yale (SNRGY); Director, Neurobiological Studies Unit, VACHS; Director, VA-CMHC Schizophrenia Research Clinic

Research Departments & Organizations

Psychiatry: Clinical Neuroscience Research Unit | Neuroscience Research Training Program (NRTP) | Schizophrenia Research Clinic

Office of Cooperative Research

Research Interests

Behavior and Behavior Mechanisms; Behavioral Disciplines and Activities; Mental Disorders; Psychiatry and Psychology; Psychological Phenomena

Research Summary

Our group has been studying the treatment and pathophysiology of schizophrenia. Our work involves the use of various psychopharmacological probes (ketamine, delta-9-THC, iomazenil, etc) to evaluate the contributions of various neurotransmitter systems (NMDA, cannabinoid, GABA, etc) to the pathophysiology of schizophrenia; laboratory studies of comorbid substance abuse in schizophrenia, (alcohol, cannabis and nicotine) and clinical trials with novel agents for schizophrenia.

Extensive Research Description


    • Neurobiology of Cannabis
    • Cannabinoids, Neural Synchrony and Information Processing
    • Cannabinoid Receptor Function in Alcoholism: Effects of D-9-THC
    • Imaging Nicotinic Acetylcholine Receptors in Schizophrenia
    • GABA Deficits and Vulnerability to Cannabinoid-Induced Psychosis
    • GABA Deficits and Vulnerability to Amphetamine-Induced Psychosis
    • Ketamine Nicotine Interactions in Humans
    • Ketamine Interactions with GLYT1 inhibitor in Humans
    • Cognitive Remediation in the Schizophrenia Trials Network
    • Varenicline for Smoking Cessation in Schizophrenia
  • Clinical Trials

    Conditions Study Title
    Diseases of the Nervous System, Mental Health & Behavioral Research A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia
    Addictive Behaviors, Alcohol Addiction, Diseases of the Nervous System, Mental Health & Behavioral Research, Tobacco Addiction Imaging the Neurochemistry of Drug Addiction With PET
    Diseases of the Nervous System, Mental Health & Behavioral Research Examination of Glutamate and mGluR5 in Psychiatric Disorders
    Mental Health & Behavioral Research Sleep Dependent Learning in Schizophrenia and Psychosis Risk Syndrome
    Mental Health & Behavioral Research, Tobacco Addiction Imaging Tobacco Smoking Withdrawal using [11C]PHNO
    Diseases of the Nervous System, Mental Health & Behavioral Research C4 Gene Dose Effects using 11C-UCB-J PET
    Mental Health & Behavioral Research Imaging mGluR5 and synaptic density in psychiatric disorders
    Mental Health & Behavioral Research Imaging SV2A in mood disorders
    Mental Health & Behavioral Research A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients
    Addictive Behaviors PET Imaging of mGLuR5 With Drug Challenge
    Mental Health & Behavioral Research Translational Neuroscience Optimization of GlyT1 Inhibitor (NCATS)
    Mental Health & Behavioral Research STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.
    Mental Health & Behavioral Research, Tobacco Addiction Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors (nic_physo)
    Addictive Behaviors, Alcohol Addiction, Genetics - Adult, Mental Health & Behavioral Research Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans

    Activities

    • Cognitive Rehabilitation in Schizophrenia - D-serine Facilitation India (2008)

      Clinical trial of the combination of D-serine (Gly site agonist) and computerized cognitive retraining to improve cognition in individuals with schizophrenia

    Selected Publications

    See list of PubMed publications

    Edit this profile